How does Burna AI address the 11% oncology death rate attributable to poor adverse event management?

Roughly 11% of deaths in oncology are attributable to poor adverse event management (industry estimate). Burna AI's leverage on that number is concentrated at three points. First, faster and more accurate attribution at the point of clinical encounter enables earlier dose modification and intervention. Second, continuous between-visit symptom monitoring through Care Journal captures toxicities that would otherwise present at the next clinic visit (Denis et al. JAMA 2019 showed a 22.5 vs 14.9 months OS benefit with structured patient self-reporting). Third, real-time cross-site visibility in multi-site trials means a safety signal in one site is visible to all stakeholders the moment it lands, not at the next monthly monitoring visit.